What is Ebola virus disease, including its transmission, clinical presentation, diagnosis, treatment, and prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ebola Virus Disease (EVD): What matters for morbidity, mortality, and quality of life

• Bold recommendation: If you suspect EVD, immediately isolate with full contact precautions and urgently arrange rRT-PCR testing; start aggressive IV fluids/electrolyte resuscitation and give an approved anti-Ebola monoclonal antibody (REGN-EB3/Inmazeb) as early as possible—these steps most reduce death and long-term disability 1.

What it is

  • Filovirus infection (Zaire ebolavirus most lethal) with untreated case-fatality up to 70–90% and rapid progression to shock and multiorgan failure if not promptly treated 1.

Transmission and incubation

  • Zoonotic spillover (likely fruit bats; also nonhuman primates/duikers), then human-to-human via direct contact with blood/body fluids, contaminated surfaces, and during care and burial practices 1.
  • Incubation ~8.5 days on average (range up to 21) 2.
  • Viral persistence: semen months–years (documented sexual transmission up to 470 days post-onset); virus detected in ocular fluid, CNS, placenta, breast milk—implications for relapse and secondary transmission 1.

Clinical presentation (time course that predicts risk)

  • Day 0–3: “Dry” symptoms—fever, headache, myalgias, arthralgias 1.
  • ~Day 4 onward: “Wet” symptoms—profuse vomiting/diarrhea (up to 10 L/day), leading to severe dehydration, electrolyte derangements, AKI, shock; hemorrhage in ~50%, usually late 1.
  • Labs: leukopenia, lymphopenia, elevated AST/ALT; DIC markers in severe disease 1.
  • Fatal cases often die 7–10 days after onset from multiorgan failure 1.

Diagnosis (do this, in order, to protect staff and patients)

  • Immediately isolate; collect only essential specimens with full PPE.
  • Test: rRT-PCR for EBOV RNA is the standard. Antigen rapid tests may aid triage but do not replace PCR 3.
  • Minimize transport; use bedside diagnostics when possible; imaging at bedside or in controlled, designated sessions if essential to care 4.

Treatment (highest impact on survival and QOL)

  1. Immediate supportive care (do not delay):
    • Large-volume IV crystalloids; correct K+, Na+, Ca2+ aggressively.
    • Manage shock (fluids, vasopressors), AKI (consider RRT at bedside with dedicated machines), and hypoxia (oxygen; airway only if essential due to exposure risk) 4, 1.
    • Early, protocolized supportive care alone can lower mortality to ~40% 1.
  2. Specific anti-EBOV therapy (prioritize the best evidence):
    • REGN-EB3 (Inmazeb): FDA-approved for Zaire ebolavirus; in the 2018 RCT, REGN-EB3 and mAb114 both significantly reduced 28-day mortality versus control, with greatest benefit when given early and at lower viral loads 1.
    • Act fast: each day of symptom delay increased odds of death by ~11% in the RCT 1.
  3. Procedures and ICU care with exposure control:
    • Intubation/CPR are high risk; ensure maximal barrier precautions. Use designated equipment; consider risks/benefits of aerosol-generating procedures; bedside dialysis preferred; decontaminate dialysate as infectious waste 4.
    • Post-mortem only if essential, in BSL3/4 conditions 4.

Common pitfalls to avoid:

  • Delayed fluids/electrolytes and delayed monoclonal therapy—both raise mortality 1.
  • Unnecessary patient transport; non-designated equipment use; lapses in PPE donning/doffing—raise nosocomial transmission risk 4.
  • Assuming recovery ends infectious risk—counsel on semen persistence and breast milk; arrange testing and safe-sex guidance 1.

Prevention (who to vaccinate, and how to protect others)

  • Vaccine: Ervebo (rVSVΔG-ZEBOV-GP) is the only FDA-licensed vaccine (for Zaire ebolavirus).
    • ACIP recommends pre-exposure vaccination for adults ≥18 years at highest occupational risk in the U.S.: outbreak responders, staff at designated Ebola treatment centers, and BSL-4 laboratorians 1.
    • Contraindication: severe allergy to rice protein (vaccine contains rice-derived recombinant HSA) 1.
  • Survivors:
    • Semen testing and safer sex: EBOV RNA can persist >1 year (up to 965 days documented); sexual transmission documented at 199 and 470 days. Use condoms and follow testing programs until two consecutive negatives 1.
    • Breastfeeding: EBOV detected up to 16 months; avoid breastfeeding until virologically cleared per public health guidance 1.
  • Health-care infection control:
    • Strict contact and droplet precautions with full PPE; consider respirators for high-risk procedures; designated equipment and areas; trained monitor for compliance 4.

How to act when you suspect a case (step-by-step)

  • Isolate immediately; notify infection control and public health 4.
  • Don full PPE; limit staff exposure; perform only essential tasks.
  • Draw labs with biosafety protocols; order EBOV rRT-PCR.
  • Start high-volume IV fluids, correct electrolytes, treat shock; begin antiemetics and antidiarrheals; initiate vasopressors if needed.
  • Administer REGN-EB3 as early as possible for confirmed or highly probable Zaire ebolavirus cases per FDA/availability 1.
  • Manage complications (AKI with bedside RRT, coagulopathy, hypoxia) while minimizing aerosol-generating procedures 4.
  • Plan survivor follow-up: eye/CNS symptoms, renal monitoring, semen testing, reproductive counseling to reduce late morbidity and transmission 1.

Notes on evidence strength and nuances:

  • Highest-quality, most recent actionable guidance for mortality/QOL reduction: ACIP MMWR (2021) on vaccine/prevention and RCT monoclonal antibody data with FDA approval of REGN-EB3; early supportive care impact repeatedly affirmed 1.
  • Infection-control logistics in HLIU/ICU are guided by consensus recommendations; evidence for aerosol risks in EVD is indirect—still treat aerosol-generating procedures as high risk to protect staff 4.
  • Epidemiologic parameters (incubation, time-to-death) are consistent across syntheses; variability reflects outbreak context 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.